Holen Sie sich die Stockscreener-App
9.42
1.62%
0.15
Design Therapeutics Inc Aktie (DSGN) Neueste Nachrichten
Analysts Set Design Therapeutics, Inc. (NASDAQ:DSGN) Target Price at $14.00 - Defense World
Design Therapeutics (DSGN) Price Target Increased by 41.00% to 11.98 - Nasdaq
Design Therapeutics (NASDAQ:DSGN) Rating Lowered to “Sell” at Wall Street Zen - Defense World
Design Therapeutics (NASDAQ:DSGN) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Design Therapeutics, Inc. (NASDAQ:DSGN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Why retail investors pile into Design Therapeutics Inc. stockJuly 2025 Technicals & High Accuracy Trade Signal Alerts - Newser
Design Therapeutics (NASDAQ:DSGN) Coverage Initiated by Analysts at Craig Hallum - MarketBeat
Design Therapeutics (NASDAQ:DSGN) Stock Rating Upgraded by Leerink Partnrs - Defense World
Minerva jumps on phase III funding, leading neuro stocks - BioWorld MedTech
Design Therapeutics (NASDAQ:DSGN) Sets New 1-Year HighHere's Why - MarketBeat
Leerink Partnrs Upgrades Design Therapeutics (NASDAQ:DSGN) to "Strong-Buy" - MarketBeat
How Design Therapeutics Inc. stock reacts to Fed rate cuts2025 Bull vs Bear & Smart Money Movement Tracker - Newser
Leerink Partners upgrades Design Therapeutics stock to Outperform on pipeline progress - Investing.com Nigeria
Leerink Partners Upgrades Design Therapeutics (DSGN) - Nasdaq
Leerink Partners upgrades Design Therapeutics stock to Outperform on pipeline progress By Investing.com - Investing.com South Africa
Design Therapeutics Shares Rise After Leerink Upgrade - marketscreener.com
Design Therapeutics, Inc. (DSGN): Analysts Upgrade to Outperform Amid Positive Price Potential - Stocks Telegraph
Craig-Hallum initiates Design Therapeutics stock with Buy rating By Investing.com - Investing.com South Africa
Craig-Hallum initiates Design Therapeutics stock with Buy rating - Investing.com
Leerink Upgrades Design Therapeutics to Outperform From Market Perform, Adjusts PT to $14 From $7 - MarketScreener
Will Design Therapeutics Inc. stock deliver shareholder valueWeekly Trend Summary & Risk Managed Investment Strategies - Newser
Design Therapeutics (DSGN) Stock Analysis Report | Financials & Insights - Benzinga
Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer - Yahoo Finance
How Design Therapeutics Inc. stock performs in weak economyNew Guidance & Safe Entry Point Alerts - Newser
Trevi Therapeutics Inc Strengthens Strategy For Clinical Design - Kalkine Media
Will Aries Agro Limited Stock Benefit From Industry Trends in YEARSupport Level Holds & Free Double Digit Growth Tips - earlytimes.in
How sustainable is Design Therapeutics Inc. stock dividend payoutWeekly Trend Summary & Breakout Confirmation Alerts - BỘ NỘI VỤ
Design Therapeutics (NASDAQ:DSGN) Trading Up 9%What's Next? - MarketBeat
Why Design Therapeutics Inc. stock is rated strong buyWeekly Market Report & Consistent Income Trade Recommendations - BỘ NỘI VỤ
Design Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Design Therapeutics (Nasdaq: DSGN) to Participate in Piper Sandler and Evercore 2025 Events - Stock Titan
Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth - simplywall.st
Design Therapeutics (NASDAQ:DSGN) Sets New 52-Week HighStill a Buy? - MarketBeat
Design Therapeutics upgraded to Outperform from Sector Perform at RBC Capital - MSN
Design Therapeutics spikes as RBC upgrades on an eventful 2026 - MSN
RBC Capital Upgrades Design Therapeutics (DSGN) - Nasdaq
Design Therapeutics, Inc.Common Stock (Nasdaq:DSGN) Stock Quote - Markets Financial Content
Design Therapeutics' Friedreich Ataxia Program Shows Potential, RBC Says - MarketScreener
Design Therapeutics stock up as RBC upgrades (DSGN:NASDAQ) - Seeking Alpha
Nutex Health Posts Strong Q3 Results, Joins PACS Group, Walmart, Cerence And Other Big Stocks Moving Higher On Thursday - Benzinga
Design Therapeutics : DSGN - 24/7 Wall St.
Design Therapeutics stock rating upgraded by RBC Capital on improved outlook - Investing.com Nigeria
RBC Upgrades Design Therapeutics to Outperform From Sector Perform, Boosts Price Target to $13 From $6, Keeps Speculative Risk - MarketScreener
Can Design Therapeutics Inc. stock sustain free cash flow growthJuly 2025 Breakouts & Safe Entry Point Identification - newser.com
Fuchs Dystrophy Clinical Trial Assessment 2025: Over 5 Global - openPR.com
Why retail investors favor Design Therapeutics Inc. stockJuly 2025 Closing Moves & Target Return Focused Stock Picks - newser.com
Is Design Therapeutics Inc. stock poised for growthTrade Analysis Summary & Safe Swing Trade Setups - newser.com
How to interpret RSI for Design Therapeutics Inc. stock2025 Price Momentum & Fast Gain Stock Trading Tips - newser.com
Can Design Therapeutics Inc. stock sustain institutional interest - newser.com
Analyzing Design Therapeutics Inc. with risk reward ratio chartsJuly 2025 Trade Ideas & Stock Timing and Entry Methods - newser.com
Technical signs of recovery in Design Therapeutics Inc.Weekly Stock Summary & Technical Buy Zone Confirmations - newser.com
Shareholder Logos Global Master Fund LP Files To Sell 120,000 Of Design Therapeutics Inc [DSGN] - TradingView
Published on: 2025-11-17 12:13:42 - newser.com
Is Design Therapeutics Inc. forming a bottoming baseMarket Sentiment Report & AI Forecast for Swing Trade Picks - newser.com
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):